Earlier this month, the long-awaited results of the TAILORx clinical trial were announced.
The findings from this study are important for early stage breast cancer patients with hormone receptor-positive breast cancer. The study results are expected to assist many patients in this group in determining whether chemotherapy should be part of their treatment.
The TAILORx findings are also interesting when viewed as part of a developing trend in treatment for early stage breast cancer away from a one-size-fits all approach toward more personalized care.
The findings were presented at the annual meeting of the American Society for Clinical Oncology (ASCO) and also published in the New England Journal of Medicine (NEJM). Continue reading